XML 38 R10.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Inventory | 12 Months Ended
--- | ---
Dec. 31, 2021
Inventory Disclosure [Abstract] |
Inventory | (4) Inventory The Company capitalizes its purchases of saleable inventory of VASCEPA from suppliers that have been qualified by the U.S. FDA and other global regulatory agencies. Inventories as of December 31, 2021 and 2020 consist of the following:
In thousands |  | December 31, 2021 |  |  | December 31, 2020 |
Raw materials |  | $ | 107,695 |  |  | $ | 50,657 |
Work in process |  |  | 41,965 |  |  |  | 30,388 |
Finished goods |  |  | 206,270 |  |  |  | 107,819 |
Inventory |  | $ | 355,930 |  |  | $ | 188,864 |
As of December 31, 2021 and 2020, we had $121.3 million and nil of Long-term inventory, respectively, as consumption is expected beyond our normal operating cycle.

X
- References No definition available. + Details
Name: | us-gaap_InventoryDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 330 -URI http://asc.fasb.org/topic&trid=2126998 + Details
Name: | us-gaap_InventoryDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration